New research shows weight-loss drugs are effective for teens and children as young as 6 years old, but younger kids who took the drugs grew more slowly than those who didn't, which could be cause for concern.
In studies presented at an obesity medicine conference this week, drugmaker Novo Nordisk showed its drug Wegovy helped elementary-school-age children with obesity lose weight, though they grew more slowly on average. Eli Lilly's drug Zepbound proved effective for adolescent weight loss. Both helped lower blood sugar and some forms of cholesterol.
The youngest children, age 6 to 11 years old, who took Novo's drug Wegovy saw their body-mass index, or BMI, drop by an average of 13.5%. To compare, those on diet and exercise programs alone saw their BMIs rise by around 3% over that time period.
"Lifestyle counseling is not, on average, an effective treatment for obesity" in children, said Aaron Kelly, a professor of pediatrics at the University of Minnesota and an author on Novo's study. "It doesn't take your hunger signals away. It doesn't take your cravings away, but the medicines do that."
Children who took Wegovy grew 1.3 inches less than those who didn't take the drug, the data showed. Kids in this age group normally grow between four to 5 inches over two years.
"Will these kids wind up shorter? I don't know. Is that a big deal for these kids? I don't know. But those are the types of things I worry about," said Dr. Robert Siegel, an obesity medicine pediatrician at Cincinnati Children's Hospital, who wasn't involved in the study.
Children with obesity are often taller than normal-weight peers. Researchers said that the drugs may be helping to slow that rapid growth to an average rate and that data over five or more years is needed to answer these questions.
"It's impossible to say whether this is their normal growth without obesity, or if this medicine by itself affected their height," said Dr. Joey Skelton, an obesity medicine specialist and professor of pediatrics at Wake Forest University School of Medicine who wasn't involved in the research. "If we lose a little bit of height, but we're able to change their health trajectory for the rest of their life, then I think it's worth it."
Genetics often play a big role in childhood obesity, which can make it harder to treat. Nearly one in five children in the U.S. lives with obesity, opening up a potentially large market for these drugs. Wall Street thinks younger patients could bring in hundreds of millions of dollars in new revenue for the drugmakers. It all depends on how willing doctors and parents are to use them, or how likely insurers are to cover them.
Also at the conference, Eli Lilly reported results of a late-stage study looking at adolescents. In its study, those who took Zepbound's BMIs dropped 18.5% on average, compared with a slight average BMI increase in the group using diet and exercise alone. Adolescents taking Zepbound grew at similar rates to those on placebo.
Eli Lilly hasn't said if or when it will file for U.S. regulatory approval. Such a move would catch it up to Novo, whose drug was approved for adolescents starting at age 12 nearly four years ago.
Following that approval, the American Academy of Pediatrics issued new guidelines that recommended doctors offer weight-loss drugs for adolescents with obesity, which was controversial.
Some experts said they didn't have enough long-term safety data, particularly as it relates to growth and development, while others said the guidelines could increase stigma around weight.
Use of weight-loss drugs among adolescents remains limited. The share of adolescents with obesity prescribed Wegovy rose to 0.9% in 2024 from 0.5% in 2023, according to data from healthcare-analytics company Truveta.
Nicholas Hackenburg, a 17-year-old high-school senior in Clyde, Ohio, was frequently chastised by doctors throughout childhood to "eat less and move more." As many sports as he tried -- soccer, wrestling, tennis, baseball -- and as many diets as he followed, he struggled to keep off any weight he had lost for more than a few months.
Genetic testing revealed that Nicholas has a variant that has been linked to severe, early-onset obesity. He has been taking a GLP-1 on and off for several years, with gaps due to changes in insurance coverage. He did experience some nausea when he was increasing his doses of the drug, but he found it manageable. Over the past 11 uninterrupted months on Ozempic, Hackenburg, who is 5'11, has lost roughly 100 pounds.
"Pains in my body are leaving. I breathe better," said Nicholas, who was bullied in middle school because of his weight. "If I could go back in time and avoid all of it, I would do it in a heartbeat."
His mother, Jessica Hackenburg, said she wishes the drugs had been available when her son was younger.
Novo's and Lilly's drugs had similar side effects in the studies to those seen in adults. Nausea and vomiting were common, which were relatively small at fewer than 200 patients per trial. Between 13 and 17% of participants dropped out of the studies entirely.
Both Novo and Lilly tracked growth, puberty and the type of weight that participants lost. In Novo's study, children taking Wegovy lost body fat but continued to gain muscle and other lean tissue as they grew.
Comments